NFE2L2 and Duchenne muscular dystrophy: Our group is currently investigating the fumarate drug, DMF, for therapeutic application in DMD [59], and we are interested in comparing the risk–benefit profile of exogenous (via DMF) versus endogenous (via ASA) fumarate-induced Nrf2 targeting.